The prevalence, persistence, and de novo development of clinical and/or radiological signs of CKD-MBD were clearly associated with serum PTH levels more than 5 times ULN (i.e., > 300 pg/ml). This evidence concerns the gene PTH and Marchiafava-Bignami disease.